Spun out of Yale University, Helix Therapeutics, Inc. develops deoxyribonucleic acid (DNA) based therapeutics. The mission of Helix had been defined as establishing cures for select genetic diseases using triplex-forming oligonucleotide (TFO) technology. Specific targeting of genetic information in human hematopoietic stem cells leads to stable, heritable correction of responsible mutations.The firm developed novel sequence-specific gene-targeting reagents for the treatment of HIV/AIDS and common genetic diseases, such as sickle cell anemia, thalassemia, and cystic fibrosis. Specific targeting of genetic information in human hematopoietic stem cells leads to stable, heritable correction of responsible mutations. While the technical achievements of the firm were useful, during 2010 - for other reasons not explained publicly - that company ceased operations. Subsequently many of the same players have come together addressing a similar agenda win a different startup.
